Plastic surgery trends show growing acceptance of aesthetic procedures as self-care, with over 28.5 million minimally ...

Law Offices of Howard G. Smith reminds investors of the upcoming August 25, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Hims & Hers Health, Inc ...

Hims & Hers Health continues to eye personalized services and global expansion. Read more on what investors should know about ...

Wegovy, a weight loss drug made famous by celebrities around the world, is on New Zealand pharmacists' shelves, but it is unfunded and could cost users around $500 a month.

The total cost of funding the state's department that administers Medicaid topped $55 billion last year including federal ...

As GLP-1 drugs like Wegovy and Ozempic grow in popularity, so too has a kind of alternative: compounded versions of the drugs ...

A fast-growing group of Americans are turning to what many call the "gray market" for obesity medicines, bringing cheap ...

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

Novo Nordisk A/S (NYSE:NVO) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company discontinued its partnership with Hims & Hers concerning selling its weight-loss drug, ...

Novo Nordisk is expanding access to its drug Wegovy through a new partnership with WeightWatchers, days after cutting ties with telehealth firm Hims & Hers. Starting July 1, WeightWatchers will ...

Under the deal, cash-paying patients can access a month’s supply of Wegovy through the Danish drugmaker’s Novocare pharmacy for $299. The one-time price will also be available through Novo’s other ...